ETS-1/RhoC signaling regulates the transcription factor c-Jun in melanoma

International Journal of Cancer

Volumn 130, Issue 12, 2012, Pages 2801-2811

  Spangler, Barbara ^a   Kappelmann, Melanie ^a   Schittek, Birgit ^b   Meierjohann, Svenja ^c   Vardimon, Lily ^d   Bosserhoff, Anja Katrin ^a   Kuphal, Silke ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

c Jun; cytoskeleton; ETS 1; melanoma; Rho

Indexed keywords

PROTEIN C JUN; RHO FACTOR; RHOC PROTEIN; TRANSCRIPTION FACTOR ETS 1; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CELL ADHESION; CONTROLLED STUDY; CYTOSKELETON; DOWN REGULATION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; TRANSCRIPTION REGULATION;

CADHERINS; CELL LINE, TUMOR; CYTOSKELETON; HUMANS; MELANOMA; NOCODAZOLE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEIN C-ETS-1; PROTO-ONCOGENE PROTEINS C-JUN; RHO GTP-BINDING PROTEINS; RHOA GTP-BINDING PROTEIN; RHOB GTP-BINDING PROTEIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 84859899492     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26277     Document Type: Article

References (50)

1. Shoo BA, Kashani-Sabet M,. Melanoma arising in African-, Asian-, Latino- and Native-American populations. Semin Cutan Med Surg 2009; 28: 96-102.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer. J Clin 2009; 59: 225-49.
3. Miller CJ, Cheung M, Sharma A, Clarke L, Helm K, Mauger D, Robertson GP,. Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol 2004; 123: 990-2. (Pubitemid 39391947)
4. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D, Halaban R,. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010; 8: 67-75.
5. thor SP, Guldberg P, Gronbaek K, Hansen MR, Kirkin AF, Seremet T, Zeuthen J, Becker JC,. In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J Immunol 1999; 163: 443-7. (Pubitemid 29295872)
6. van Elsas A, Hurwitz AA, Allison JP,. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190: 355-66. (Pubitemid 29374833)
7. Hess J, Angel P, Schorpp-Kistner M,. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004; 117: 5965-73. (Pubitemid 40123963)
8. Vogt PK, Bader AG,. Jun: stealth, stability, and transformation. Mol Cell 2005; 19: 432-3. (Pubitemid 41140000)
9. Spangler B, Vardimon L, Bosserhoff AK, Kuphal S,. Post-transcriptional regulation controlled by E-cadherin is important for c-Jun activity in melanoma. Pigment Cell Melanoma Res 11 A.D; 24: 148-64.
10. Ivanov VN, Bhoumik A, Krasilnikov M, Raz R, Owen-Schaub LB, Levy D, Horvath CM, Ronai Z,. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell 2001; 7: 517-28. (Pubitemid 32706344)
11. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson S, Ronai Z,. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 2007; 11: 447-60. (Pubitemid 46670078)
12. Lopez-Bergami P, Kim H, Dewing A, Goydos J, Aaronson S, Ronai Z,. c-Jun regulates phosphoinositide-dependent kinase 1 transcription: implication for Akt and protein kinase C activities and melanoma tumorigenesis. J Biol Chem 2010; 285: 903-13.
13. Hibi M, Lin A, Smeal T, Minden A, Karin M,. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 1993; 7: 2135-48. (Pubitemid 23336140)
14. Fuchs SY, Dolan L, Davis RJ, Ronai Z,. Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase. Oncogene 1996; 13: 1531-5. (Pubitemid 26354201)
15. Wei W, Jin J, Schlisio S, Harper JW, Kaelin WG, Jr., The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 2005; 8: 25-33. (Pubitemid 40991812)
16. Morton S, Davis RJ, McLaren A, Cohen P,. A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. EMBO J 2003; 22: 3876-86. (Pubitemid 36975714)
17. Laine A, Ronai Z,. Ubiquitin chains in the ladder of MAPK signaling. Sci STKE 2005; 2005: re5.
18. Lallemand D, Ham J, Garbay S, Bakiri L, Traincard F, Jeannequin O, Pfarr CM, Yaniv M,. Stress-activated protein kinases are negatively regulated by cell density. EMBO J 1998; 17: 5615-26. (Pubitemid 28445973)
19. Reisfeld S, Vardimon L,. Cell to cell contacts control the transcription activity of the glucocorticoid receptor. Mol Endocrinol 1994; 8: 1224-33. (Pubitemid 24292599)
20. Knirsh R, Ben Dror I, Spangler B, Matthews GD, Kuphal S, Bosserhoff AK, Vardimon L,. Loss of E-cadherin-mediated cell-cell contacts activates a novel mechanism for up-regulation of the proto-oncogene c-Jun. Mol Biol Cell 2009; 20: 2121-9.
21. Andersen H, Mejlvang J, Mahmood S, Gromova I, Gromov P, Lukanidin E, Kriajevska M, Mellon JK, Tulchinsky E,. Immediate and delayed effects of E-cadherin inhibition on gene regulation and cell motility in human epidermoid carcinoma cells. Mol Cell Biol 2005; 25: 9138-50. (Pubitemid 41429101)
22. Ruegg J, Holsboer F, Turck C, Rein T,. Cofilin 1 is revealed as an inhibitor of glucocorticoid receptor by analysis of hormone-resistant cells. Mol Cell Biol 2004; 24: 9371-82. (Pubitemid 39391675)
23. Oren A, Herschkovitz A, Ben Dror I, Holdengreber V, Ben Shaul Y, Seger R, Vardimon L,. The cytoskeletal network controls c-Jun expression and glucocorticoid receptor transcriptional activity in an antagonistic and cell-type-specific manner. Mol Cell Biol 1999; 19: 1742-50. (Pubitemid 29098232)
24. Polak P, Oren A, Ben Dror I, Steinberg D, Sapoznik S, Arditi-Duvdevany A, Vardimon L,. The cytoskeletal network controls c-Jun translation in a UTR-dependent manner. Oncogene 2006; 25: 665-76. (Pubitemid 43214693)
25. Bishop AL, Hall A,. Rho GTPases and their effector proteins. Biochem J 2000; 348 (Pt 2): 241-55. (Pubitemid 30345195)
26. Clark EA, Golub TR, Lander ES, Hynes RO,. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406: 532-5. (Pubitemid 30625739)
27. Wang L, Yang L, Luo Y, Zheng Y,. A novel strategy for specifically down-regulating individual Rho GTPase activity in tumor cells. J Biol Chem 2003; 278: 44617-25. (Pubitemid 37377216)
28. Rothhammer T, Hahne JC, Florin A, Poser I, Soncin F, Wernert N, Bosserhoff AK,. The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci 2004; 61: 118-28. (Pubitemid 38121905)
29. Huang CC, Papas TS, Bhat NK,. A variant form of ETS1 induces apoptosis in human colon cancer cells. Oncogene 1997; 15: 851-6. (Pubitemid 27390138)
30. Lelievre E, Mattot V, Huber P, Vandenbunder B, Soncin F,. ETS1 lowers capillary endothelial cell density at confluence and induces the expression of VE-cadherin. Oncogene 2000; 19: 2438-46. (Pubitemid 30323477)
31. Bellovin DI, Bates RC, Muzikansky A, Rimm DL, Mercurio AM,. Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res 2005; 65: 10938-45. (Pubitemid 41713362)
32. Bellovin DI, Simpson KJ, Danilov T, Maynard E, Rimm DL, Oettgen P, Mercurio AM,. Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene 2006; 25: 6959-67. (Pubitemid 44684836)
33. Hsu M, Andl T, Li G, Meinkoth JL, Herlyn M,. Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci 2000; 113: 1535-42. (Pubitemid 30312502)
34. Pece S, Gutkind JS,. Signaling from E-cadherins to the MAPK pathway by the recruitment and activation of epidermal growth factor receptors upon cell-cell contact formation. J Biol Chem 2000; 275: 41227-33. (Pubitemid 32054955)
35. Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR,. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 2004; 23: 1739-48. (Pubitemid 38649637)
36. Molina-Ortiz I, Bartolome RA, Hernandez-Varas P, Colo GP, Teixido J,. Overexpression of E-cadherin on melanoma cells inhibits chemokine-promoted invasion involving p190RhoGAP/p120ctn-dependent inactivation of RhoA. J Biol Chem 2009; 284: 15147-57.
37. Asnaghi L, Vass WC, Quadri R, Day PM, Qian X, Braverman R, Papageorge AG, Lowy DR,. E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases. Oncogene 2010; 29: 2760-71.
38. Boone B, Van Gele M, Lambert J, Haspeslagh M, Brochez L,. The role of RhoC in growth and metastatic capacity of melanoma. J Cutan Pathol 2009; 36: 629-36.
39. Hakem A, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, Khokha R, Mak TW,. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 2005; 19: 1974-79. (Pubitemid 41247955)
40. Keehn CA, Smoller BR, Morgan MB,. Expression of the ets-1 proto-oncogene in melanocytic lesions. Mod Pathol 2003; 16: 772-7. (Pubitemid 37011072)
41. Hall A,. The cytoskeleton and cancer. Cancer Metastasis Rev 2009; 28: 5-14.
42. Jiang L, Liu X, Kolokythas A, Yu J, Wang A, Heidbreder CE, Shi F, Zhou X,. Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer 2010; 127: 505-12.
43. Hill CS, Wynne J, Treisman R,. The Rho family GTPases RhoA. Rac1, and. CDC42Hs regulate transcriptional activation by SRF. Cell 1995; 81: 1159-70.
44. Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N, Miki T, Gutkind JS,. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 1995; 81: 1137-46.
45. Samarakoon R, Goppelt-Struebe M, Higgins PJ,. Linking cell structure to gene regulation: signaling events and expression controls on the model genes PAI-1 and CTGF. Cell Signal 2010; 22: 1413-19.
46. Babakov VN, Petukhova OA, Turoverova LV, Kropacheva IV, Tentler DG, Bolshakova AV, Podolskaya EP, Magnusson KE, Pinaev GP,. RelA/NF-kappaB transcription factor associates with alpha-actinin-4. Exp Cell Res 2008; 314: 1030-8.
47. Coutts AS, Weston L, La Thangue NB,. A transcription co-factor integrates cell adhesion and motility with the p53 response. Proc Natl Acad Sci USA 2009; 106: 19872-7.
48. Roth DM, Moseley GW, Glover D, Pouton CW, Jans DA,. A microtubule-facilitated nuclear import pathway for cancer regulatory proteins. Traffic 2007; 8: 673-86. (Pubitemid 46785150)
49. Zhang G, Dass CR, Sumithran E, Di Girolamo N, Sun LQ, Khachigian LM,. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst 2004; 96: 683-96. (Pubitemid 38660231)
50. Wang T, Li QH, Hao GP, Zhai J,. Antitumor activity of decoy oligodeoxynucleotides targeted to NF-kappaB in vitro and in vivo. Asian Pac J Cancer Prev 2010; 11: 193-200.